UNCAGED PodcastA sit down with Bant Breen on clinical development and the introduction of technology into the…We recently sat down with Stefano Ferrara on The UNCAGED Show to discuss his career as Director of Clinical Science at Beigene, a global…Jun 28
TFS HealthScienceExploring the Evolving Landscape of EU Clinical Trials Post-RegulationAs of February 2024, we are less than one year out from 31 January 2025, a date that marks the end of the three-year transition period…Apr 6
Manish KhatriThe evolving future of Randomized Controlled Trials and the role of external control data (ECD)Randomized Controlled Trials (RCTs), where the patient population is randomly assigned to either a treatment group or a control group, have…Sep 5, 20222Sep 5, 20222
Ochre BioOchre Bio Leadership Series — Eduardo Martins on NASH Clinical DevelopmentLast year, Ochre Bio sat down (virtually) with Eduardo Martins, (who is now the CMO at Sagimet Biosciences), to discuss the challenges of…Jun 28, 2021Jun 28, 2021
myTomorrowsUnderstanding Expanded Access, Compassionate Use, and Similar TermsPatients with a serious disease or condition who have run out of satisfactory treatment options and cannot enroll in a Clinical Trial are…May 19, 2020May 19, 2020
UNCAGED PodcastA sit down with Bant Breen on clinical development and the introduction of technology into the…We recently sat down with Stefano Ferrara on The UNCAGED Show to discuss his career as Director of Clinical Science at Beigene, a global…Jun 28
TFS HealthScienceExploring the Evolving Landscape of EU Clinical Trials Post-RegulationAs of February 2024, we are less than one year out from 31 January 2025, a date that marks the end of the three-year transition period…Apr 6
Manish KhatriThe evolving future of Randomized Controlled Trials and the role of external control data (ECD)Randomized Controlled Trials (RCTs), where the patient population is randomly assigned to either a treatment group or a control group, have…Sep 5, 20222
Ochre BioOchre Bio Leadership Series — Eduardo Martins on NASH Clinical DevelopmentLast year, Ochre Bio sat down (virtually) with Eduardo Martins, (who is now the CMO at Sagimet Biosciences), to discuss the challenges of…Jun 28, 2021
myTomorrowsUnderstanding Expanded Access, Compassionate Use, and Similar TermsPatients with a serious disease or condition who have run out of satisfactory treatment options and cannot enroll in a Clinical Trial are…May 19, 2020